WO2019083328A3 - 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제 - Google Patents

안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제 Download PDF

Info

Publication number
WO2019083328A3
WO2019083328A3 PCT/KR2018/012849 KR2018012849W WO2019083328A3 WO 2019083328 A3 WO2019083328 A3 WO 2019083328A3 KR 2018012849 W KR2018012849 W KR 2018012849W WO 2019083328 A3 WO2019083328 A3 WO 2019083328A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
anthocyanin
cancer
fucoidan
immuno
Prior art date
Application number
PCT/KR2018/012849
Other languages
English (en)
French (fr)
Other versions
WO2019083328A2 (ko
WO2019083328A9 (ko
Inventor
나건
장봉근
조영엄
서정덕
이주영
Original Assignee
가톨릭대학교 산학협력단
주식회사 제이비케이랩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단, 주식회사 제이비케이랩 filed Critical 가톨릭대학교 산학협력단
Priority to US16/759,364 priority Critical patent/US20200376066A1/en
Priority to CN201880083898.XA priority patent/CN111565758A/zh
Priority to JP2020543440A priority patent/JP6961100B2/ja
Priority to EP18870322.7A priority patent/EP3701970A4/en
Priority claimed from KR1020180128919A external-priority patent/KR102134307B1/ko
Publication of WO2019083328A2 publication Critical patent/WO2019083328A2/ko
Publication of WO2019083328A3 publication Critical patent/WO2019083328A3/ko
Publication of WO2019083328A9 publication Critical patent/WO2019083328A9/ko
Priority to US18/087,842 priority patent/US20230132001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 안토시아닌과 후코이단의 이온결합에 의해 형성되는 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 조성물에 관한 기술로, 보다 상세하게 생체적합성 및 생분해성이 높은 천연추출물인 후코이단의 음이온을 안토시아닌의 양이온과 이온결합시킨 안토시아닌-후코이단 복합체는 생체 내 산성 조건에서도 안토시아닌의 안정성과 용해도를 향상시킴으로써, 안토시아닌의 생체 내 면역활성을 증가시키는 효과를 확인함에 따라, 상기 안토시아닌-후코이단 복합체를 면역증강제, 면역항암제 및 항암제 부작용 완화용 항암보조제로 제공하고자 한다.
PCT/KR2018/012849 2017-10-27 2018-10-26 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제 WO2019083328A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US16/759,364 US20200376066A1 (en) 2017-10-27 2018-10-26 Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient
CN201880083898.XA CN111565758A (zh) 2017-10-27 2018-10-26 包含花色素苷-岩藻依聚糖复合物为活性成分的免疫增强剂、免疫治疗抗癌剂和抗癌治疗不良反应缓解剂
JP2020543440A JP6961100B2 (ja) 2017-10-27 2018-10-26 アントシアニン−フコイダン複合体を有効成分として含有する免疫増強剤、免疫抗ガン剤及び抗ガン剤の副作用緩和剤
EP18870322.7A EP3701970A4 (en) 2017-10-27 2018-10-26 IMMUNITY STIMULATION AGENT, IMMUNOTHERAPEUTIC ANTI-CANCER AGENT, AND ADVERSE ANTI-CANCER THERAPY MITIGATION AGENT CONTAINING ANTHOCYANINE-FUCOIDANE COMPLEX AS ACTIVE INGREDIENT
US18/087,842 US20230132001A1 (en) 2017-10-27 2022-12-23 Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170141184 2017-10-27
KR10-2017-0141184 2017-10-27
KR10-2018-0128919 2018-10-26
KR1020180128919A KR102134307B1 (ko) 2017-10-27 2018-10-26 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/759,364 A-371-Of-International US20200376066A1 (en) 2017-10-27 2018-10-26 Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient
US18/087,842 Continuation US20230132001A1 (en) 2017-10-27 2022-12-23 Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient

Publications (3)

Publication Number Publication Date
WO2019083328A2 WO2019083328A2 (ko) 2019-05-02
WO2019083328A3 true WO2019083328A3 (ko) 2019-06-27
WO2019083328A9 WO2019083328A9 (ko) 2019-08-15

Family

ID=66246467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012849 WO2019083328A2 (ko) 2017-10-27 2018-10-26 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제

Country Status (1)

Country Link
WO (1) WO2019083328A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120000388A (ko) * 2010-06-25 2012-01-02 한국방송통신대학교 산학협력단 면역력 증강을 통한 항아토피 활성을 갖는 슈퍼 Ｃ3ＧＨｉ 흑자미벼
KR20130130573A (ko) * 2012-05-22 2013-12-02 경상대학교산학협력단 미역귀와 멍게껍질의 혼합물 추출액을 포함하는 아토피성 피부염 개선용 조성물
KR20150066004A (ko) * 2013-12-05 2015-06-16 주식회사 해림후코이단 나노버블 후코이단 수소수 및 그 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120000388A (ko) * 2010-06-25 2012-01-02 한국방송통신대학교 산학협력단 면역력 증강을 통한 항아토피 활성을 갖는 슈퍼 Ｃ3ＧＨｉ 흑자미벼
KR20130130573A (ko) * 2012-05-22 2013-12-02 경상대학교산학협력단 미역귀와 멍게껍질의 혼합물 추출액을 포함하는 아토피성 피부염 개선용 조성물
KR20150066004A (ko) * 2013-12-05 2015-06-16 주식회사 해림후코이단 나노버블 후코이단 수소수 및 그 제조방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOUNG, M. G. ET AL.: "Antioxidant, Anticancer and Immune Activation of Anthocyanin Fraction from Rubus Coreanus Miquel Fruits (Bokbunja", KOREAN J. MEDICINAL CROP SCI., vol. 20, no. 4, 2012, pages 259 - 269, XP053030799, DOI: 10.7783/KJMCS.2012.20.4.259 *
MIN, D. H. ET AL.: "Fucoidan Based Nanocomplex for Improving Antioxidant Activity of Anthocyanin", BIOMATERIALS RESEARCH, vol. 16, no. 2, 2012, pages 60 - 66, XP055621220 *
See also references of EP3701970A4 *

Also Published As

Publication number Publication date
WO2019083328A2 (ko) 2019-05-02
WO2019083328A9 (ko) 2019-08-15

Similar Documents

Publication Publication Date Title
WO2016178586A3 (en) Collagen compositions and preparation and uses thereof
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2021006035A (es) Formulaciones cannabinoides estables.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2018014868A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2018010788A (es) Composicion oftalmologica.
BR112018006922A2 (pt) composições farmacêuticas estabilizantes de camptotecina
EP3538187A4 (en) MULTIMODAL SURGICAL GAS DELIVERY SYSTEM FOR KEEPING A STABLE BODY CAVE PRESSURE WHILE SUCTION IN THE BODY CAVE
WO2019027387A3 (en) PRODUCT CONTAINING EXOSOMES OF VEGETABLE ORIGIN
EP4248981A3 (en) Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3701970A4 (en) IMMUNITY STIMULATION AGENT, IMMUNOTHERAPEUTIC ANTI-CANCER AGENT, AND ADVERSE ANTI-CANCER THERAPY MITIGATION AGENT CONTAINING ANTHOCYANINE-FUCOIDANE COMPLEX AS ACTIVE INGREDIENT
WO2019083328A3 (ko) 안토시아닌-후코이단 복합체를 유효성분으로 함유하는 면역증강제, 면역항암제 및 항암제 부작용 완화제
EP2826497A3 (en) Intra-articular injection and implant attachment of molecules consisting of lubricin and extracellular superoxide dismutase or hyaluronic acid and extracellular superoxide dismutase
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
PH12016501500B1 (en) Topical formulations of heparin
PH12019502335A1 (en) Thermo-responsive gelling artificial lacrima
PH12019501946A1 (en) Liquid composition containing pradofloxacin
RU2014140385A (ru) Композиция для повышения адаптации организма человека в высокогорье
WO2015126151A3 (ko) 신곡 추출물을 포함하는 상처 치료용 조성물
JOP20200108A1 (ar) توليفات شحمية
MY179369A (en) Composition for improving eyes health

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020543440

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018870322

Country of ref document: EP

Effective date: 20200527

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18870322

Country of ref document: EP

Kind code of ref document: A2